Serum Reactive Oxygen Metabolites as a Predictor of Clinical Disease Activity Index, Simplified Disease Activity Index, and Boolean Remissions in Rheumatoid Arthritis Patients Treated With Biologic Agents.
Serum Reactive Oxygen Metabolites as a Predictor of Clinical Disease Activity Index, Simplified Disease Activity Index, and Boolean Remissions in Rheumatoid Arthritis Patients Treated With Biologic Agents.
复制标题
DOI：
10.7759/cureus.19759
复制
发表时间：
2021-11
期刊：
影响因子：
--
通讯作者：
Nakagawa K
中科院分区：
文献类型：
--
作者：
Nakajima A;Terayama K;Sonobe M;Akatsu Y;Saito J;Norimoto M;Taniguchi S;Kubota A;Aoki Y;Nakagawa K
前言活性氧代谢物（ROM）是血液中的代谢产物氢过氧化物，其血清水平与类风湿关节炎（RA）患者的疾病活动评分28（DAS 28）相关。在这项研究中，我们的目的是调查是否ROM将预测临床疾病活动指数（CDAI）缓解，简化的疾病活动指数（SDAI）缓解，或布尔缓解。材料与方法51例生物制剂（BA）初治RA患者纳入本观察性研究。研究12周时ROM、C反应蛋白、基质金属蛋白酶-3、DAS 28-红细胞沉降率（ESR）、CDAI、SDAI和健康评估问卷（HAQ）与52周时DAS 28、CDAI、SDAI和布尔缓解率之间的相关性。结果DAS28、CDAI、SDAI和布尔缓解率分别为66.7%、52.9%、54.9%和54.9%。多变量logistic回归分析显示，12周时的ROM和HAQ与52周时的CDAI、SDAI和布尔缓解相关。受试者操作特征分析表明，CDAI、SDAI和布尔缓解的截止值为389.5 U.Car。结论：BA初始治疗12周时的活性氧代谢产物是52周时CDAI、SDAI和布尔缓解的预测因子。血清ROM水平可能是目前治疗RA早期缓解的一个有用的生物标志物。
Introduction Reactive oxygen metabolites (ROMs) are metabolite hydroperoxides in the blood, and their serum levels were associated with the disease activity score 28 (DAS28) in patients with rheumatoid arthritis (RA). In this study, we aimed to investigate whether ROMs would be predictive of the clinical disease activity index (CDAI) remission, simplified disease activity index (SDAI) remission, or Boolean remission. Materials and methods Fifty-one biologic agents (BA)-naïve RA patients were included in this observational study. Associations between ROMs, C-reactive protein, matrix metalloproteinase-3, DAS28-erythrocyte sedimentation rate (ESR), CDAI, SDAI, and health assessment questionnaire (HAQ) at 12 weeks and the DAS28, CDAI, SDAI, and Boolean remission rates at 52 weeks were investigated. Results The DAS28, CDAI, SDAI, and Boolean remission rates at 52 weeks were 66.7, 52.9, 54.9, and 54.9%, respectively. A multivariate logistic regression analysis revealed that ROMs and HAQ at 12 weeks were associated with the CDAI, SDAI, and Boolean remission at 52 weeks. Receiver operating characteristic analyses demonstrated that the cut-off value for CDAI, SDAI, and Boolean remission was 389.5 U.Carr. Conclusion Reactive oxygen metabolites at 12 weeks of initial treatment with BAs was a predictor for CDAI, SDAI, and Boolean remission at 52 weeks. Serum levels of ROMs may be a useful biomarker in the current treatment strategy aiming at early remission of RA.
影响因子：
--
作者：
Takahashi H;Aoki Y;Saito J;Nakajima A;Sonobe M;Akatsu Y;Taniguchi S;Yamada M;Koyama K;Akiyama Y;Shiga Y;Inage K;Orita S;Eguchi Y;Maki S;Furuya T;Akazawa T;Koda M;Yamazaki M;Ohtori S;Nakagawa K
通讯作者：
Nakagawa K